ondansetron has been researched along with paroxetine in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Artursson, P; Mateus, A; Matsson, P | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Duman, EN; Erciyes, N; Kadioglu, M; Kalyoncu, NI; Kesim, M; Yaris, E | 1 |
| Borah, M; Radhakrishnan, M; Ramamoorthy, R | 1 |
| Bazanella Sampaio, T; Mozzaquatro Gai, B; Nogueira, CW; Pinton, S; Trevisan da Rocha, J; Zeni, G | 1 |
| Dhamee, MS; Gollapudy, S; Kumar, V | 1 |
| Bhatt, S; Devadoss, T; Jindal, A; Kumar, B; Mahesh, R; Pandey, DK | 1 |
| Bétry, C; Bundgaard, C; Haddjeri, N; Mørk, A; Overstreet, D; Pehrson, AL; Sanchez, C | 1 |
| Afzal, A; Ara, I; Farooqi, R; Khan, A; Khan, BT | 1 |
| Becker, C; Becker, G; Boehlke, C; Buroh, S; Coune, B; Hercz, D; Joos, L; Meerpohl, JJ; Schwarzer, G | 1 |
2 review(s) available for ondansetron and paroxetine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacological interventions for pruritus in adult palliative care patients.
Topics: Animals; Capsaicin; Cromolyn Sodium; gamma-Aminobutyric Acid; Humans; Naltrexone; Ondansetron; Palliative Care; Paroxetine; Receptors, Opioid; Rifampin; Zinc Sulfate | 2023 |
14 other study(ies) available for ondansetron and paroxetine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
Topics: Animals; Brain; Dialysis; HEK293 Cells; High-Throughput Screening Assays; Humans; Pharmaceutical Preparations; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
The different roles of 5-HT(2) and 5-HT(3) receptors on antinociceptive effect of paroxetine in chemical stimuli in mice.
Topics: Abdominal Pain; Acetic Acid; Analgesia; Analgesics; Animals; Dose-Response Relationship, Drug; Drug Synergism; Female; Injections, Intraperitoneal; Ketanserin; Male; Mice; Mice, Inbred BALB C; Morphine; Naloxone; Ondansetron; Pain Measurement; Paroxetine; Receptors, Serotonin, 5-HT2; Receptors, Serotonin, 5-HT3 | 2005 |
Antidepressant-like effects of serotonin type-3 antagonist, ondansetron: an investigation in behaviour-based rodent models.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antidepressive Agents; Behavior, Animal; Cyclohexanols; Desipramine; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Exploratory Behavior; Fluoxetine; Hindlimb Suspension; Male; Maze Learning; Mice; Motor Activity; Olfactory Bulb; Ondansetron; Paroxetine; Rats; Rats, Wistar; Serotonin 5-HT3 Receptor Agonists; Serotonin 5-HT3 Receptor Antagonists; Stress, Psychological; Venlafaxine Hydrochloride | 2008 |
Effects of diphenyl diselenide on depressive-like behavior in ovariectomized mice submitted to subchronic stress: involvement of the serotonergic system.
Topics: Animals; Antidepressive Agents; Benzene Derivatives; Cerebral Cortex; Depression; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Female; Hippocampus; Immobility Response, Tonic; Menopause; Mice; Mice, Inbred Strains; Mitochondria; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Ondansetron; Organoselenium Compounds; Ovariectomy; Pargyline; Paroxetine; Piperazines; Pyridines; Ritanserin; Serotonergic Neurons; Serotonin Antagonists; Stress, Psychological | 2012 |
A case of serotonin syndrome precipitated by fentanyl and ondansetron in a patient receiving paroxetine, duloxetine, and bupropion.
Topics: Aged; Analgesics, Opioid; Anesthesia, General; Bupropion; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Fentanyl; Humans; Mastectomy; Ondansetron; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome; Thiophenes | 2012 |
Antidepressant and anxiolytic-like effects of 4n, a novel 5-HT3 receptor antagonist using behaviour based rodent models.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Depression; Emotions; Mice; Olfactory Bulb; Ondansetron; Paroxetine; Photoperiod; Quinoxalines; Rats; Rats, Wistar; Reserpine; Serotonin 5-HT3 Receptor Antagonists; Swimming | 2012 |
A 5-HT3 receptor antagonist potentiates the behavioral, neurochemical and electrophysiological actions of an SSRI antidepressant.
Topics: Animals; Depression; Disease Models, Animal; Dorsal Raphe Nucleus; Drug Synergism; Electrophysiological Phenomena; Hippocampus; Male; Microdialysis; Ondansetron; Paroxetine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin 5-HT3 Receptor Antagonists | 2015 |
Effect of paroxetine on intestinal motility in the presence of ondansetron.
Topics: Animals; Antiemetics; Drug Interactions; Female; Gastrointestinal Motility; Ileum; Male; Muscle, Smooth; Nausea; Ondansetron; Paroxetine; Rabbits; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Vomiting | 2020 |